Page 28 - Aesthetics&Dermatology_11_2018

RESEARCH REPORTS

TRANEXAMIC ACID

FOR MELASMA

Adding oral tranexamic acid as adjuvant therapy is effective for treating refractory melasma,
according to recently published research.

Melasma is, traditionally, difficult to issue, researchers revealed a 8.6 percent (48) were male.
treat. To date, its pathogenesis is twice-daily oral tranexamic acid Most patients (95 percent) were
unclear. But, data shows including dose reduced melasma effects. The categorized as having treatment-
tranexamic acid–a synthetic article was selected as a “game resistant melasma because they
derivative of lysine–in an ongoing changer” study in the Oct. 30, 2018 had received previous melasma
treatment protocol can produce issue of the Journal of the American therapy without any satisfactory
improvement in most patients. Academy of Dermatology. results. Of the group, 530 (94.5
percent) had previously used topical
Previous research discovered The 2016 study, which included depigmentation creams, and 199
tranexamic acid slows melanin melasma patients from a (35.5 percent) underwent lasers or
synthesis by inhibiting the dermatologic center in Singapore intense pulsed light treatments.
plasminogen/plasmin pathway. from January 2010 to June 2014,
Doing so blocks interactions looked at clinical characteristics, In some cases, investigators
between melanocytes and treatment outcomes, and adverse reported, controllable factors could
keratinocytes. Consequently, using effects of TA therapy. Oral have contributed to their melasma.
either oral or topical tranexamic acid tranexamic acid was used as an Existing research links hormonal
can decrease melasma-associated adjuvant therapy to topical or therapy to melasma appearance.
skin pigmentation and reverse any laser treatments in 98.2 percent of In this study, 21 patients (3.7
melasma-related dermal changes, patients. percent) used oral contraceptives,
including reduced redness and a 6 (1.1 percent) used hormone
decreased number of vessels. THE DATA replacement therapy, and 2 (0.4
percent) used an intrauterine
In a retrospective analysis, Investigators included data from contraceptive device before
published in a 2016 Journal of the 561 patients. Of that group, 91.4
American Academy of Dermatology percent (513) were female, and 29

28